

September 03, 2024

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Received Product Registration Licenses for two products in Myanmar

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that we, Zota Health Care Limited (the “Company”) have received product registration licenses for below mentioned two products from the Ministry of Health Department of Food and Drug Administration, Myanmar:

Sr. No.	Name of Product	Therapeutic Category
1	LANZOCID-30 (Each hard gelatin capsule contains: Lansoprazole USP 30mg (as enteric coated pellets)	Drugs For Acid Related Disorders
2	S-AMLOZED 2.5 (Each uncoated tablet contains: S-Amlodipine Besilate eq. to S-Amlodipine 2.5mg)	Calcium Channel Blocker

We have received aforementioned product registration licenses for the validity period of five years; further the same can be renewed after expiration. The Company shall commence export of these products in Myanmar in a near term.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352